On December 5, 2024, Sharps Technology, Inc., a Nevada corporation, disclosed the signing of subscription agreements with specific institutional investors. These agreements outline the issuance and sale of 248,430 shares of the Company’s Common Stock, valued at $0.0001 per share. The transaction was set at a price of $1.95 per share, resulting in total proceeds of $484,438 for the Company before deduction of placement agent fees and commissions.
The Shares involved in the offering were made available in compliance with Nasdaq rules and the Company’s Form 1-A (the “Offering Statement”). This initial filing with the Securities and Exchange Commission (SEC) under the Securities Act of 1933 was most recently amended on November 18, 2024, and officially qualified on December 3, 2024.
As part of the financial disclosures, the Company also stated that the subscribed shares will be governed under agreements dated December 5, 2024. Additionally, an interactive data file embedded with the Inline XBRL document was submitted as Exhibit 104 in the report.
The signing of this report on December 6, 2024, occurred in accordance with the regulations of the Securities Exchange Act of 1934, as amended. The report was formally authorized on behalf of the registrant by Robert Hayes, who serves as the Chief Executive Officer of Sharps Technology, Inc.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sharps Technology’s 8K filing here.
About Sharps Technology
Sharps Technology, Inc, a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc was incorporated in 2017 and is based in Melville, New York.
Featured Stories
- Five stocks we like better than Sharps Technology
- Where Do I Find 52-Week Highs and Lows?
- Lululemon Surges On Q3 Report: Analysts Step in To Support Market
- What to Know About Investing in Penny Stocks
- 10 Safe Investments with High Returns
- Insider Trades May Not Tell You What You Think
- 3 Utility Stocks That Will Benefit from Less Regulation
